Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ovarian carcinoma frequently metastasizes to the peritoneum, both locally in the pelvis and elsewhere. Computed tomography (CT) has a limited ability to identify peritoneal implants with a diameter of 2 cm or less. Three cases of subphrenic, diaphragmatic peritoneal implants, preoperatively at CT thought to represent liver parenchymal metastases, are presented. The difficulty in the differentiation of diaphragmatic peritoneal implants from metastases to the capsule and parenchyma of the liver is discussed. To achieve a radical liver resection in patients with ovarian carcinoma, metastatic peritoneal implants must be excluded during operation.
 ...
PMID:Peritoneal ovarian metastases simulating liver parenchymal metastases. 161 10

A patient with ovarian carcinoma was evaluated for skeletal metastasis with a routine whole body bone scan. Although no bone metastases were visualized, there was dramatic accumulation of tracer in the soft tissues of the abdomen. CT revealed calcifying soft tissue metastases on the liver surface, the bowel serosa, and in the pelvis corresponding to the abnormal areas of Tc-99m MDP uptake. Tumor necrosis and ongoing calcification within the metastatic sites are possible explanations for this unusual soft tissue concentration of the bone-seeking radiopharmaceutical. In patients with metastatic ovarian carcinoma, careful review of extraosseous regions on bone scan images may provide valuable diagnostic information.
 ...
PMID:Concentration of Tc-99m MDP in ovarian carcinoma and its soft tissue metastases. 193 5

Tumour associated monoclonal antibodies HMFG1, HMFG2, H17E2, AUA1, EGFR1, labelled with 123-Iodine or 111-Indium, were used to detect primary and metastatic cancer by external body scintigraphy in patients with ovarian, breast and non-small cell lung cancer (NSCC). Successful localisation was seen in all patients with primary and 80% of the metastatic NSCC, 50% of primary and 70% of metastatic breast cancer lesions and in 80% of patients with metastatic ovarian cancer. On the other hand, imaging carried with a radiolabelled non-specific monoclonal antibody produced positive results in 3 out of 5 cases with primary NSCC. Therefore non-specific imaging should be further studied in clinical research for the evaluation of the specificity of radioimmunodetection. In our therapeutic trials we have so far treated 29 patients with resistant ovarian cancer, with intraperitoneal 131I-labelled antibodies (HMFG1, HMFG2, AUA1, H17E2), 11 patients with recurrent pleural and pericardial effusions by intracavitary 131I-labelled antibodies, 10 patients with brain gliomas by intravenous or intracarotid infusion of 131I-EGFR1 and two patients with hepatic metastases from colon carcinoma by intrahepatic infusion of 131I-anti-CEA antibodies. The preliminary results from these therapeutic studies seem to be encouraging and are discussed in detail in this review.
 ...
PMID:Radiolabelled monoclonal antibodies in tumour diagnosis and therapy. 240 91

Fifty-seven patients with metastatic ovarian cancer arising from extra-genital sites are analysed. 80.8%, 14% and 5.3% of the primary cancers were from gastrointestinal tract (GI), breast and lung, respectively. The primary carcinoma was diagnosed before the discovery of ovarian tumor in 24 patients. The ovarian and primary carcinomas were found simultaneously in 11 patients (including one autopsy), while in 22 patients, the primary cancer was not discovered until the ovarian tumor had been resected. Both ovaries were involved in 60% of GI cancer and 12.5% of breast cancer. 91.2% of the patients were found to have metastasis to other tissues and organs outside the ovary. Of patients with GI cancer, 80.8% had metastasis to the abdomino-pelvic cavity, 73.7% had ascites and 52.2% had lymphatic metastasis. The majority of the patients with breast cancer had lymphatic (75%) and hematogenous (50%) metastases. In this series, the prognosis was poor in all the patients with an average survival time of 11 months. 63.2% and 86% of the patients died within 1 and 2 years. These facts indicate that ovarian involvement may be an important part of widespread dissemination from the primary cancer.
 ...
PMID:[Metastatic cancer in the ovary--report of 57 cases]. 256 55

Abnormal CA 15-3 antigen levels are found in the serum of most patients with advanced breast carcinoma. Elevations of this marker are less frequently seen in other malignancies. Circulating CA 15-3 levels might be useful in the differential diagnosis of the primary site of cancer. We studied the levels of CA 15-3 in 500 patients with different non-mammary cancers. Elevations of CA 15-3 (greater than 40 U ml-1) were observed in all types of epithelial malignancies, especially in ovarian (46%), respiratory (26%) and liver (30%) carcinomas. Abnormal values were observed in some patients with haematological malignancies and sarcomas, but not in melanoma or neurological tumours. CA 15-3 antigen levels correlated with the extent of non-mammary malignant tumours. Patients with locoregional cancer had a significantly smaller proportion of elevations of the antigen than those with distant metastases (12% versus 35%, P less than 0.001). In particular, elevated CA 15-3 levels were observed in 70% of patients with metastatic ovarian cancer. Liver involvement by cancer did not produce more elevations of CA 15-3 than metastases to other organs (32% versus 39%). Simultaneous determination of circulating CA 15-3 and CA 125 antigens in 58 patients with cancer of the ovary showed that CA 15-3 is elevated in some cases of ovarian carcinoma with non-elevated CA 125, and that CA 15-3 and CA 125 are distinct antigens. We conclude that circulating CA 15-3 antigen levels can be found elevated in virtually all types of cancer, particularly when distant metastases are present. Therefore, CA 15-3 levels should not be used in the differential diagnosis of the primary site in patients with metastatic malignancies of unknown origin. Evaluation of CA 15-3 levels may enhance the sensitivity of CA 125 in monitoring the course of ovarian carcinoma.
 ...
PMID:Circulating CA 15-3 antigen levels in non-mammary malignancies. 293 Jun 93

Tumour associated monoclonal antibodies (MAbs) HMFG1, HMFG2 and H17E2, labelled with 123iodine or 111indium, were used to detect primary and metastatic cancer by external body scintigraphy in patients with ovarian, breast and non-small cell lung cancer (NSCC). Successful localisation was seen in all patients with primary and 80% of the metastatic NSCC, 50% of primary and 70% of metastatic breast cancer lesions and in 80% of patients with metastatic ovarian cancer. On the other hand, imaging carried with a radiolabelled non-specific MAb produced positive results in 3 out of 5 cases with primary NSCC. Therefore, non-specific imaging should be further studied in clinical research for the evaluation of the specificity of radioimmunodetection. A therapeutic procedure which has shown promise is that of intracavity administration of radiolabelled antibodies. Twenty-nine patients with resistant ovarian cancer have been treated with intraperitoneal 131I-labelled MAbs (HMFG1, HMFG2, AUA1, H17E2). There were no significant responses in 8 patients with gross disease. There were 2 responses in 15 assessable patients with tumour nodules of less than 2 cm in diameter. Out of 6 patients with microscopic disease, 4 are disease-free with follow-up time of 6-40 months (mean = 17.5 months).
 ...
PMID:Antibody-guided diagnosis and therapy of malignant lesions. 316 48

The role of appendectomy in the management of epithelial ovarian cancer is unknown as a staging and cytoreductive procedure. In this series, the appendix was found to have metastatic disease in 40 of 78 patients (51%) and in 40 of 57 patients (70%) with advanced disease (stage III/IV). Occult or microscopic disease was found only in two patients (5%) with grossly normal appearing appendices. The appendix as a site of metastatic ovarian cancer is common with advanced stages (stage III/IV) and rare with early disease.
 ...
PMID:The appendix and its metastatic potential in epithelial ovarian cancer. 382 87

The macrophage colony-stimulating factor (CSF-1) is best known as a hematopoietic cytokine important to macrophage activation. Recently, the importance of CSF-1 and its receptor (encoded by the c-fms proto-oncogene) in epithelial ovarian cancer has also been recognized, with overexpression of CSF-1 denoting poor prognosis in ovarian cancer patients. During macrophage activation, CSF-1 promotes urokinase-type plasminogen activator (uPA) activity; in macrophages and in malignant cells of lung, breast, colon, and prostatic origin, uPA activity is strongly correlated with the ability to invade and, in the malignant cells, to metastasize. While there is clear evidence of CSF-1 and uPA expression in primary and metastatic ovarian cancer, the significance of their expression to invasion of these cells has not been explored. We find that all of our ovarian cancer cell lines which we have studied co-express CSF-1 and uPA transcripts and protein. Urokinase expression in these ovarian cancer cell lines correlates with the degree of tumorigenicity in nude mice, with the most virulent tumor resulting from Hey cells, a strong expressor of uPA. We studied the invasion of these primary and established ovarian cancer cells through a Matrigel (reconstituted basement membrane matrix) barrier. The ability of ovarian cancer cells to invade is strongly correlated with endogenous CSF-1 expression (Pearson's correlation, r = 0.91; P = 0.01). A total of 0.90 +/- 0.16% of Bix3 cells (very weak expressor of CSF-1) invaded through the barrier, in contrast to 6.95 +/- 0.75% of Hey cells (strong CSF-1 expressor) and 10.44 +/- 2.33% of Bixler cells (the strongest CSF-1 expressor). We studied the ability of two of the cell lines to invade human laminin and type IV collagen (Bix3, a weak invader of Matrigel, and Hey, a strong invader), to determine (a) whether our results on a Matrigel matrix may represent a relevant model for invasion in humans and (b) whether there is a potential confounding effect from the cytokines and proteases in Matrigel. On this human simple matrix, we confirm that Bix3 is a weakly invasive cell line (0.33 +/- 0.04% invasion) which contrasted to the strongly invasive Hey cell line (8.51 +/- 0.47%). Treatment of Bix3 cells with exogenous CSF-1 stimulates percentage of invasion by 2-fold and results in a similar increase in the level of uPA transcripts and cellular associated uPA antigen. Furthermore, cell surface-bound uPA increased from 74% in the absence of CSF-1 to 100% (fully saturated) in the presence of CSF-1.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. 788 68

The aim of this study was to investigate biological heterogeneity between primary and metastatic ovarian cancer lesions from individual patients as a means of elucidating steps in clinical progression. Cancer tissue from 61 untreated patients with ovarian surface epithelial-stromal tumours was examined. p53 expression detected immunocytochemically by the PAb1801 antibody, DNA content evaluated by flow cytometry, and cell proliferation evaluated as the [3H]thymidine labelling index were investigated in primary tumours and corresponding synchronous metastases. The frequency of p53 positivity was similar in primary (62%) and metastatic (66%) sites, with an agreement between the two lesions from the same patient in 97% of the cases. Similarly, aneuploidy frequency (80%) and DNA indices were superimposable in primary and metastatic lesions from the same patient, with a 94% agreement. The frequency of aneuploidy was higher in p53-positive than in p53-negative lesions. An overall poor agreement (rs = 0.44) was observed for proliferative activity of primary and metastatic lesions, due to a heterogeneous profile in omental with respect to primary tumours, which was mainly evident in p53-positive cancers. Conversely, cell proliferation of peritoneal, abdominal and pelvic lesions was qualitatively similar to that of the primary tumour in 88% of patients.
 ...
PMID:p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours. 886 4

Invasiveness to the peritoneum reconstituted with a mesothelial cell line and Engelbreth-Holm-Swam extract by metastatic cancer cell lines of the uterine cervix, endometrium, and ovary was always higher than that by primary cell lines. The invasiveness by metastatic ovarian cancer cell lines was significantly stronger than that by the other gynecological primary or metastatic cell lines. In the clinical ovarian cancers studied, cancer cells from the metastatic lesion were more invasive than those from the primary lesion. This suggests that metastatic ovarian cancer cells might inherently possess strong invasiveness to the peritoneum. The assay system used in the present study is useful in investigating the clinical behavior and basic biology of peritoneal dissemination.
Invasion Metastasis 1996
PMID:Novel screening technique for dissemination potential of ovarian cancer cells to peritoneum. 937 Dec 29


1 2 3 4 5 6 7 Next >>